Biocon: Co's Pertuzumab Is Now The First Biosimilar To Receive An EMA CHMP Approval Recommendation Using A New Customized Clinical Method.

 21 Sep 2026 08:56 AM

Biocon: Co's Pertuzumab Is Now The First Biosimilar To Receive An EMA CHMP Approval Recommendation Using A New Customized Clinical Method.

Biocon: Company Plans Analyst And Investor Meeting On September 11

 08 Sep 2026 05:09 PM

Biocon: Company Plans Analyst And Investor Meeting On September 11

Biocon: Company Plans Analyst And Investor Meeting On September 4th

 31 Aug 2026 08:58 PM

Biocon: Company Plans Analyst And Investor Meeting On September 4th

True North Looking To Sell Shares Worth Rs 700 Cr In Co - NDTV Profit ( Biocon )

 28 Aug 2026 09:51 AM

True North Looking To Sell Shares Worth Rs 700 Cr In Co - NDTV Profit ( Biocon )

Biocon: Company Gets Approval For Pegfilgrastim Biosimilar From Japan's Health Ministry

 25 Aug 2026 08:36 AM

Biocon: Company Gets Approval For Pegfilgrastim Biosimilar From Japan's Health Ministry

Biocon: Bernstein on Biocon Upgrades with Target Price of ₹326 as US FDA approval for Yesintek autoinjectors improves patient convenience and retention, though longer-term growth remains constrained by rising competition and faster adoption of IL-23 therapies.

 19 Aug 2026 09:08 AM

Biocon: Bernstein on Biocon Upgrades with Target Price of ₹326 as US FDA approval for Yesintek autoinjectors improves patient convenience and retention, though longer-term growth remains constrained by rising competition and faster adoption of IL-23 therapies.

Biocon: Company Gets U.S. FDA Approval For Yesintek (Ustekinumab-KFCE) Single-Dose Autoinjector

 18 Aug 2026 08:55 AM

Biocon: Company Gets U.S. FDA Approval For Yesintek (Ustekinumab-KFCE) Single-Dose Autoinjector

Biocon: HSBC on Biocon Maintains Buy with Target Price of ₹490 as 1Q biosimilars sales were stable at ~US$300mn with stronger sales expected in 2H and beyond, while successful execution of new biosimilar launches, profitability improvement and cash-flow generation remain key to the turnaround.

 07 Aug 2026 08:57 AM

Biocon: HSBC on Biocon Maintains Buy with Target Price of ₹490 as 1Q biosimilars sales were stable at ~US$300mn with stronger sales expected in 2H and beyond, while successful execution of new biosimilar launches, profitability improvement and cash-flow generation remain key to the turnaround.

Biocon: Jefferies on Biocon Maintains Hold with Target Price of ₹410 as Q1 was weak across all three divisions and management views June quarter as the trough, expecting improvement in 2HFY27 through biosimilar scale-up and higher generic utilisation; FY27-29 EBITDA estimates were cut 1-5%.

 07 Aug 2026 08:57 AM

Biocon: Jefferies on Biocon Maintains Hold with Target Price of ₹410 as Q1 was weak across all three divisions and management views June quarter as the trough, expecting improvement in 2HFY27 through biosimilar scale-up and higher generic utilisation; FY27-29 EBITDA estimates were cut 1-5%.

Biocon: Bernstein on Biocon Maintains Underperform with Target Price of ₹326 as Q1 revenue grew 10% and EBITDA 7%, but sales remained ~5% below estimates, with biosimilars up 16% YoY yet missing estimates by 6%; H2 improvement is expected but likely insufficient to justify current valuations.

 07 Aug 2026 08:57 AM

Biocon: Bernstein on Biocon Maintains Underperform with Target Price of ₹326 as Q1 revenue grew 10% and EBITDA 7%, but sales remained ~5% below estimates, with biosimilars up 16% YoY yet missing estimates by 6%; H2 improvement is expected but likely insufficient to justify current valuations.

Biocon: Citi on Biocon Maintains Sell with Target Price of ₹360 as 1QFY27 missed expectations due to weaker research services and biosimilars, with revenue up 10% largely on currency benefits while biosimilar constant-currency growth was only 5% and EBITDA margin fell to 25.5% amid pricing pressure and competition.

 07 Aug 2026 08:58 AM

Biocon: Citi on Biocon Maintains Sell with Target Price of ₹360 as 1QFY27 missed expectations due to weaker research services and biosimilars, with revenue up 10% largely on currency benefits while biosimilar constant-currency growth was only 5% and EBITDA margin fell to 25.5% amid pricing pressure and competition.

Biocon: Expects Syngene International To Perform Well Between October And March.

 06 Aug 2026 01:56 PM

Biocon: Expects Syngene International To Perform Well Between October And March.

Biocon: Co. Anticipates Strong Start For Aflibercept Biosimilar With Existing Contracts, Projected Gradual Increase In Market Share, And Stronger Growth Expected In H2. - Concall Update

 06 Aug 2026 10:30 AM

Biocon: Co. Anticipates Strong Start For Aflibercept Biosimilar With Existing Contracts, Projected Gradual Increase In Market Share, And Stronger Growth Expected In H2. - Concall Update

Biocon: GLP-1 Product Line Continues To Be A Major Growth Factor - Concall Update

 06 Aug 2026 10:19 AM

Biocon: GLP-1 Product Line Continues To Be A Major Growth Factor - Concall Update

Biocon: Expands Its Global Manufacturing Network To Strengthen Regional Supply In France, Portugal, Slovenia, And Spain.

 06 Aug 2026 10:11 AM

Biocon: Expands Its Global Manufacturing Network To Strengthen Regional Supply In France, Portugal, Slovenia, And Spain.

BIOCON: Q1 CONS NET PROFIT 1.41B RUPEES VS 314M (YOY)

 05 Aug 2026 04:54 PM

BIOCON: Q1 CONS NET PROFIT 1.41B RUPEES VS 314M (YOY)

BIOCON: Q1 REVENUE 43.4B RUPEES VS 39.42B (YOY)

 05 Aug 2026 04:54 PM

BIOCON: Q1 REVENUE 43.4B RUPEES VS 39.42B (YOY)

BIOCON: Q1 EBITDA 8.5B RUPEES VS 7.49B (YOY) || Q1 EBITDA MARGIN 19.54% VS 19% (YOY)

 05 Aug 2026 04:54 PM

BIOCON: Q1 EBITDA 8.5B RUPEES VS 7.49B (YOY) || Q1 EBITDA MARGIN 19.54% VS 19% (YOY)

Biocon: Company Gets Health Canada Approval For Yesintak Ustekinumab Autoinjector Pen To Treat Autoimmune Diseases.

 29 Jul 2026 08:34 AM

Biocon: Company Gets Health Canada Approval For Yesintak Ustekinumab Autoinjector Pen To Treat Autoimmune Diseases.

Biocon: Biocon Malaysia Gets EMA Approval For New Insulin Drug Production Unit

 16 Jul 2026 08:51 AM

Biocon: Biocon Malaysia Gets EMA Approval For New Insulin Drug Production Unit